Last reviewed · How we verify
Stimulant
Stimulant, developed by Florida International University, is a marketed drug primarily indicated for occasional constipation relief. Its key composition patent is set to expire in 2028, providing a period of exclusivity and potential market protection. The primary risk is the lack of revenue data and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Stimulant |
|---|---|
| Also known as | long-acting methylphenidate, long-acting mixed amphetamine salts, Adderall, Concerta, Aptensio, Daytrana |
| Sponsor | Florida International University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Occasional constipation relief
Common side effects
Key clinical trials
- Substance Misuse To Psychosis for Stimulants (PHASE2, PHASE3)
- Dronabinol in Total Knee Arthroplasty (TKA) (PHASE4)
- Kentucky Women's Justice Community Overdose Innovation Network - Phase II (NA)
- Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails (NA)
- Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol (PHASE3)
- Health Outcomes by Neighborhood - Baltimore
- tTIS Targeted of the Striatum as an Intervention for MUD Patients (NA)
- LDART for Stimulant Use Disorder (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |